Atogepant for preventing migraine (TA973)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 May 2024
Rimegepant for treating migraine (TA919)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023
Rimegepant for preventing migraine (TA906)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 July 2023
Eptinezumab for preventing migraine (TA871)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 March 2023
Fremanezumab for preventing migraine (TA764)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Erenumab for preventing migraine (TA682)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 March 2021
Galcanezumab for preventing migraine (TA659)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 November 2020
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 June 2012
STS101 for treating acute migraine [TSID11782]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Galcanezumab for migraine [TSID10663]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Botulinum toxin type A for preventing episodic migraine [ID6450]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zavegepant for treating acute migraine [TSID11998]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Eptinezumab for preventing cluster headache attacks TSID 12087Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC